GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (STU:26CA) » Definitions » Common Stock

ImmunityBio (STU:26CA) Common Stock : €0.06 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Common Stock?

ImmunityBio's quarterly common stock declined from Sep. 2023 (€0.06 Mil) to Dec. 2023 (€0.06 Mil) but then increased from Dec. 2023 (€0.06 Mil) to Mar. 2024 (€0.06 Mil).

ImmunityBio's annual common stock increased from Dec. 2021 (€0.04 Mil) to Dec. 2022 (€0.04 Mil) and increased from Dec. 2022 (€0.04 Mil) to Dec. 2023 (€0.06 Mil).


ImmunityBio Common Stock Historical Data

The historical data trend for ImmunityBio's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Common Stock Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
- 0.03 0.04 0.04 0.06

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.06 0.06 0.06

ImmunityBio Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


ImmunityBio (STU:26CA) Business Description

Traded in Other Exchanges
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.

ImmunityBio (STU:26CA) Headlines

No Headlines